AI assistant
Sending…
Dianthus Therapeutics, Inc. /DE/ — Director's Dealing 2022
Feb 17, 2022
31874_dirs_2022-02-17_17ed73cd-587a-4ae6-9e7c-7510f2fc7eca.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Magenta Therapeutics, Inc. (MGTA)
CIK: 0001690585
Period of Report: 2022-02-15
Reporting Person: Nichols David Wayne (Chief Technical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-15 | Stock Option (Right to Buy) | $3.19 | A | 75000 | Acquired | 2032-02-14 | Common Stock (75000) | Direct |
Footnotes
F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is February 1, 2022.
More from Dianthus Therapeutics, Inc. /DE/
Declaration of Voting Results & Voting Rights Announcements
2026
May 22
Earnings Release
2026
May 5
Annual Report
2026
Apr 9
Proxy Solicitation & Information Statement
2026
Apr 9
Director's Dealing
2026
Mar 26
Regulatory Filings
2026
Mar 26
Director's Dealing
2026
Mar 17
Major Shareholding Notification
2026
Feb 17
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4